Showing results (21-30 of 65) with videos related to

Sort By:
Pageof 7
JTO Clinical and Research Reports|February 27, 2023
Massive Thymic Hyperplasia Masquerading as Cancer: A Case Report and Review of the LiteratureEmily Stern Gatof, Sarmad H Jassim, Leah Ahn, et al.
Precision Cancer Medicine|August 11, 2020
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2017
Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung AdenocarcinomaDeepa Rangachari, Paul A VanderLaan, Meghan Shea, et al.
JTO Clinical and Research Reports|March 30, 2023
ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor-Responsive Lung Cancer Driver OncogeneZachary R Schoepflin, Emmeline Academia, Soravis A Osataphan, et al.
Cancer Treatment Communications|January 24, 2017
Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practiceDeepa Rangachari, Lauren Drake, Mark S Huberman, et al.
JTO Clinical and Research Reports|January 17, 2024
The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase InhibitorsIkei S Kobayashi, William Shaffer, Hollis Viray, et al.
Clinical Lung Cancer|July 7, 2016
EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-ReviewYuri Sheikine, Deepa Rangachari, Danielle C McDonald, et al.
Pageof 7